EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Perrigo Co's enterprise value is $6,957 Mil.
Perrigo Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $534 Mil. Therefore, Perrigo Co's EV-to-EBITDA for today is 13.02.
The historical rank and industry rank for Perrigo Co's EV-to-EBITDA or its related term are showing as below:
PRGO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.16 Med: 15.93 Max: 40.92
Current: 13.02
During the past 13 years, the highest EV-to-EBITDA of Perrigo Co was 40.92. The lowest was -4.16. And the median was 15.93.
PRGO's EV-to-EBITDA is ranked better than 53.29% of 730
companies
in the Drug Manufacturers industry
Industry Median: 14.17
vs PRGO: 13.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Perrigo Co EV-to-EBITDA Historical Data
The historical data trend for Perrigo Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Perrigo Co's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Perrigo Co's EV-to-EBITDA falls into.
Perrigo Co's current Enterprise Value is $6,957 Mil.
Perrigo Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $534 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (NYSE:PRGO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Perrigo Co's share price for today is $26.74.
Perrigo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Perrigo Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRGO has been successfully added to your 